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Summary
Background Psoriasis symptoms have a signiﬁcant negative impact on health-related
quality of life, impairing physical functioning and well-being.
Objective To evaluate the impact of brodalumab, a human anti-interleukin-17R
monoclonal antibody, on psoriasis symptom severity as measured by a novel
patient-reported outcome measure, the Psoriasis Symptom Inventory, and derma-
tology-speciﬁc health-related quality of life as measured by the Dermatology Life
Quality Index (DLQI).
Methods This was a secondary analysis of a phase II, randomized, double-blind,
placebo-controlled clinical study of patients with moderate-to-severe psoriasis
(n = 198) treated with brodalumab or placebo. This analysis assessed Psoriasis
Symptom Inventory scores and DLQI scores over time. Analyses were conducted
on all patients who were randomized and received one or more injections of the
study drug according to intention to treat using last observation carried forward
to impute missing data.
Results At week 12, subjects in the brodalumab groups had signiﬁcant improve-
ments in mean Psoriasis Symptom Inventory total scores [85 (70 mg), 158
(140 mg), 162 (210 mg) and 127 (280 mg)] compared with placebo (48).
Mean improvements in DLQI were clinically meaningful (≥ 57) in the brodalu-
mab groups (62, 91, 96a n d7 1, respectively) and signiﬁcantly greater than
placebo (31). Improvements in Psoriasis Symptom Inventory were observed as
early as week 2 and in DLQI by week 4. All eight Psoriasis Symptom Inventory
item scores improved signiﬁcantly among the brodalumab groups by week 12.
Conclusions Results were from a single randomized clinical trial and may not
generalize to broader patient populations. However, treatment with brodalumab
provided signiﬁcant improvement in psoriasis symptoms in patients with moder-
ate-to-severe psoriasis.
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￿ Psoriasis has a signiﬁcant negative impact on health-related quality of life.
What does this study add?
￿ Brodalumab treatment provided statistically signiﬁcant improvement in psoriasis
symptoms and functional outcomes in patients with moderate-to-severe psoriasis.
￿ These results support the further clinical development of brodalumab to treat
patients with moderate-to-severe psoriasis.
Plaque psoriasis is a life-long chronic condition that even
when treated can remain bothersome for most patients. The
severity of physical symptoms of psoriasis, including itch, pain
and discomfort, is correlated with disease-related quality of
life and self-reported disease severity.
1,2 The primary goal of
psoriasis treatment is to control disease symptoms, minimizing
their negative effects on the patient’s health-related quality of
life (HRQoL) associated with impaired physical functioning
and well-being.
3–5 The psychosocial and physical impairments
related to psoriasis affect HRQoL to an extent similar to the
effects of other chronic diseases such as depression and hyper-
tension,
3,4 with 71% of respondents in a 2008 U.S. National
Psoriasis Foundation survey reporting that psoriasis was a sig-
niﬁcant problem in everyday life; 63% reported signiﬁcant
feelings of being self-conscious, 58% reported feelings of
embarrassment and more than a third reported avoiding social
activities and limiting dating or intimate interactions.
6 Impor-
tantly, successful treatment of psoriasis has been shown to
improve HRQoL.
7,8
Patient-reported outcomes (PROs) are important to under-
stand the patient’s perspective of disease and determine how
treatments alter the psychosocial and physical impairments
related to the disease by providing information not captured
by clinician-assessed measures.
9–11 However, generic PRO
instruments commonly used in dermatology studies, such as
the 36-Item Short Form Health Survey, do not assess symp-
toms speciﬁc to psoriasis. While the Dermatology Life Quality
Index (DLQI) is a dermatology-speciﬁc HRQoL measure fre-
quently used in clinical trials of psoriasis, it includes only a
single item on psoriasis-related symptoms and does not ade-
quately provide content coverage for psoriasis-speciﬁc symp-
tom measurement. Other PROs used to assess symptoms in
psoriasis clinical trials include single items on speciﬁc symp-
toms (e.g. itching, pain) with little documentation of mea-
surement properties.
11 The use of a PRO that adequately
captures symptoms associated with psoriasis is important in
assessing treatment efﬁcacy, as the severity of psoriasis symp-
toms are the most relevant and important attribute when
patients assessed symptoms associated with their psoriasis.
12–14
The Psoriasis Symptom Inventory was developed as a psoria-
sis-speciﬁc patient-reported measure of symptom severity
12,13
and has demonstrated good reliability and validity in patients
with psoriasis.
15,16
In this study, we used the Psoriasis Symptom Inventory to
assess psoriasis symptoms following treatment with brodalu-
mab (AMG 827), a human monoclonal antibody against inter-
leukin (IL)-17 receptor A (IL-17RA) that blocks the biological
activity of the cytokines IL-17A, IL-17F, IL-17A/F, IL-17C and
IL-25. In a phase II trial, brodalumab was shown to improve
clinical outcomes in patients with moderate-to-severe plaque
psoriasis.
17 At week 12, there was a > 85% mean improve-
ment in Psoriasis Area and Severity Index (PASI) scores in the
140- and 210-mg brodalumab groups compared with a 16%
improvement in the placebo group, and 75% improvement in
PASI (PASI 75) was achieved by > 75% of the 140 and
210 mg brodalumab-treated subjects.
17 As a secondary analy-
sis of this clinical trial data, we examined severity of psoriasis
symptoms (Psoriasis Symptom Inventory) and dermatology-
speciﬁc quality of life (DLQI) before and after brodalumab
treatment.
Materials and methods
Study design
This was an analysis of a phase II, randomized, double-blind,
placebo-controlled clinical study of patients with moderate-to-
severe psoriasis. Subjects with PASI score ≥ 12 and percentage
of psoriasis-affected body surface area (BSA) ≥ 10% were eli-
gible for the phase II study. Patients were randomly assigned
to receive placebo or brodalumab, at a dose of 70 mg,
140 mg or 210 mg, administered subcutaneously every
2 weeks, or at a dose of 280 mg every 4 weeks. The primary
objective of the phase II clinical trial was to establish a dose–
response efﬁcacy proﬁle of brodalumab compared with pla-
cebo as measured by the percentage improvement in PASI
from baseline to week 12. Secondary and exploratory end-
points included PASI 50/75/90/100, affected BSA, score on
the static physician’s global assessment (sPGA), DLQI score,
and Psoriasis Symptom Inventory score. The study protocol
was approved by the institutional review board or ethics
committee at each participating site. Details of the study and
© 2013 The Authors. British Journal of Dermatology
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17
Patient-reported outcomes
The Psoriasis Symptom Inventory, an eight-item measure to
assess the severity of psoriasis symptoms
12,13 was completed
by subjects at baseline and weeks 2, 4, 8 and 12. The eight
symptoms include itch, redness, scaling, burning, cracking,
stinging, ﬂaking and pain. ‘Scaling’ refers to the skin forming
plates or scales that represent compacted desquamated layers
of stratum corneum, which may then peel off; ‘ﬂaking’ refers
simply to loss of dry skin cells. Subjects rated the severity of
each symptom on a 5-point Likert-type rating scale ranging
from 0 (not at all) to 4 (very severe). Individual item scores
were summed for a total score, which ranged from 0 to 32.
The Psoriasis Symptom Inventory was administered as two
recall versions (24-h and 7-day recall) in this study. The 24-h
version was administered to compare performance of the two
versions and was administered only at study visits and not as
a daily diary; thus it does not give full coverage over the time
period of the study. The two Psoriasis Symptom Inventory
Table 1 Baseline demographics and characteristics
Placebo (n = 38)
Brodalumab
Q2W Q4W
70 mg (n = 39) 140 mg (n = 39) 210 mg (n = 40) 280 mg (n = 42)
Sex (male), n (%) 22 (58) 22 (56) 28 (72) 25 (62) 30 (71)
Race, n (%)
White 32 (84) 36 (92) 37 (95) 34 (85) 36 (86)
Black 3 (8) 0 (0) 1 (3) 1 (2) 1 (2)
Asian 1 (3) 1 (3) 0 (0) 2 (5) 3 (7)
Other 2 (5) 2 (5) 1 (3) 3 (8) 2 (5)
Age (years) 418 (144) 421 (111) 440 (117) 421 (122) 423 (122)
Weight (kg) 869 (206) 888 (220) 924 (237) 904 (204) 915 (229)
PASI 189( 5 9) 188( 5 7) 194( 8 0) 206( 7 8) 179( 5 5)
Affected BSA (%) 235 (128) 241 (128) 249 (169) 250 (155) 213 (110)
Data represent mean (SD) unless otherwise indicated. BSA, body surface area affected; PASI, Psoriasis Area and Severity Index; Q2W, every
2 weeks; Q4W, every 4 weeks.
Table 2 Baseline Psoriasis Symptom Inventory and Dermatology Life Quality Index (DLQI) scores
Placebo (n = 38)
Brodalumab
Q2W Q4W
70 mg (n = 39) 140 mg (n = 39) 210 mg (n = 40) 280 mg (n = 42)
Psoriasis Symptom Inventory score, 7-day
Total 198( 6 4) 177( 7 4) 182( 6 6) 189( 7 1) 176( 7 0)
Itch 28( 0 9) 25( 1 0) 25( 0 9) 27( 0 8) 24( 0 9)
Redness 27( 0 8) 26( 0 9) 26( 0 9) 28( 0 9) 25( 0 9)
Stinging 22( 1 2) 19( 1 4) 19( 1 1) 18( 1 2) 18( 1 1)
Cracking 22( 1 0) 21( 1 1) 22( 1 1) 22( 1 1) 21( 1 2)
Scaling 27( 0 9) 26( 0 9) 24( 1 0) 28( 0 8) 25( 1 0)
Burning 21( 1 1) 18( 1 3) 21( 1 1) 19( 1 2) 18( 1 1)
Flaking 28( 0 9) 26( 1 0) 25( 0 8) 28( 0 8) 26( 0 9)
Pain 21( 1 1) 18( 1 3) 21( 1 2) 21( 1 2) 18( 1 2)
DLQI score
Total 133( 7 0) 124( 7 2) 111( 6 7) 114( 6 4) 108( 6 6)
Symptoms and feelings 43( 1 5) 42( 1 4) 40( 1 5) 39( 1 5) 36( 1 6)
Daily activities 31( 1 7) 28( 1 8) 24( 1 6) 21( 1 6) 22( 1 8)
Leisure 23( 2 3) 22( 2 0) 18( 1 8) 16( 1 8) 19( 1 9)
Work and school 09( 1 0) 08( 1 1) 06( 0 8) 06( 0 8) 07( 0 9)
Personal relationships 17( 1 7) 14( 1 8) 17( 1 9) 20( 1 8) 14( 1 6)
Treatment 10( 1 2) 09( 1 1) 07( 1 0) 12( 1 1) 10( 1 0)
Data represent mean (SD). Q2W, every 2 weeks; Q4W, every 4 weeks.
© 2013 The Authors. British Journal of Dermatology
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results.
15 This analysis focused on the 7-day version of the
Psoriasis Symptom Inventory. Analyses of the Psoriasis Symp-
tom Inventory included mean total and item scores over time,
mean improvement in Psoriasis Symptom Inventory total score
over time, and proportion of subjects with individual item
scores (0–4) for each symptom. Complete improvement of
psoriasis-related symptoms was deﬁned as achieving the best
possible Psoriasis Symptom Inventory total score of ‘0’.
The DLQI is a 10-item measure assessing a patient’s self-
assessment of their quality of life and problems associated
with dermatological disease encompassing aspects such as
symptoms and feelings, daily activities, leisure, work and
school, personal relationships and treatment.
18 DLQI total
scores range from 0 to 30, with lower scores indicating better
dermatology-speciﬁc quality of life. The DLQI was completed
by subjects at baseline and weeks 4, 8 and 12. DLQI total
scores were categorized as total score of 0 and total score of 0
or 1 both representative of no effect at all on HRQoL.
Statistical analysis
Analyses were conducted on all patients who were random-
ized and received one or more injections of the study drug
according to the intention-to-treat principle. All analyses
were conducted using SAS
 version 92 (SAS Institute, Cary,
NC, U.S.A.). Baseline demographic and disease characteristics
were summarized descriptively with means and SD for contin-
uous variables and percentages for categorical variables. Psoria-
sis Symptom Inventory and DLQI efﬁcacy endpoints were
assessed by an analysis of variance (ANOVA) with a generalized
linear model adjusting for baseline body mass index group
(≤ 35, > 35). Threshold analyses used proportion of subjects
meeting threshold values of Psoriasis Symptom Inventory
scores of 0 and DLQI scores of 0 or 1. A P-value < 005 was
required for signiﬁcance using two-sided hypothesis tests. All
P-values are nominal and not adjusted for multiplicity. Last
observation carried forward (LOCF) was used to impute miss-
ing data.
Table 3 Improvement from Baseline in Psoriasis Symptom Inventory and Dermatology Life Quality Index (DLQI) total scores
Placebo (n = 38)
Brodalumab
Q2W Q4W
70 mg (n = 39) 140 mg (n = 39) 210 mg (n = 40) 280 mg (n = 42)
Psoriasis Symptom Inventory total score
Week 2
n 30 37 34 37 41
Mean (SD) 42( 5 2) 73( 7 1) 97( 6 2) 123( 7 4) 105( 7 1)
P-value 006 0001 < 00001 00001
Week 4
n 33 37 37 39 41
Mean (SD) 32( 6 8) 99( 8 3) 134( 6 7) 155( 6 5) 107( 7 0)
P-value < 00001 < 00001 < 00001 < 00001
Week 8
n 33 37 37 39 41
Mean (SD) 45( 6 2) 93( 9 4) 150( 7 7) 163( 6 4) 126( 7 0)
P-value 00072 < 00001 < 00001 < 00001
Week 12
n 33 37 37 39 41
Mean (SD) 48( 6 5) 85( 9 2) 158( 7 7) 162( 7 2) 127( 8 1)
P-value 0042 < 00001 < 00001 < 00001
DLQI total score
Week 4
n 36 37 39 39 40
Mean (SD) 24( 5 1) 52( 6 2) 73( 5 4) 82( 5 9) 63( 5 2)
P-value 0033 00002 < 00001 0003
Week 8
n 37 37 39 40 41
Mean (SD) 30( 5 3) 61( 6 9) 89( 6 8) 94( 5 8) 71( 5 8)
P-value 0030 < 00001 < 00001 0003
Week 12
n 37 37 39 40 41
Mean (SD) 31( 6 6) 62( 7 0) 91( 6 8) 96( 6 1) 71( 6 8)
P-value 0047 00001 < 00001 0007
P-value is based on a generalized linear model adjusting for body mass index group (≤ 35, > 35) and is for comparison between each brod-
alumab group and placebo without multiplicity adjustment; last observation carried forward was used to impute missing data. Q2W, every
2 weeks; Q4W, every 4 weeks.
© 2013 The Authors. British Journal of Dermatology
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A total of 198 subjects were enrolled: 160 to brodalumab and
38 to placebo (Table 1). The Psoriasis Symptom Inventory
was completed at both baseline and week 12 by 186 (94%)
subjects, with a slightly lower proportion of subjects in the
placebo group completing the Psoriasis Symptom Inventory at
both time points than in the brodalumab groups. Baseline
demographics and clinical characteristics were similar across
treatment groups; 64% of subjects were male, mean age was
42 years and mean PASI score was 191 (Table 1). Details on
baseline demographics and disease characteristics have previ-
ously been reported.
17 The mean Psoriasis Symptom Inventory
total score for the full study population was 180 and was
similar across groups (Table 2). Mean baseline Psoriasis Symp-
tom Inventory item scores, DLQI total scores, and DLQI
domain scores were consistent across groups (Table 2).
At week 12, subjects in the brodalumab groups had signiﬁ-
cant improvements in mean Psoriasis Symptom Inventory total
score compared with the placebo group (Table 3). Signiﬁcant
differences in mean Psoriasis Symptom Inventory total score
and item scores were observed as early as week 2 and were
maintained through week 12 for the brodalumab groups
(Figs 1a and 2). There were no observable improvements in
the 210-mg group over the 140-mg group, but the improve-
ments in the 280-mg group were nominally higher than those
of the other brodalumab treatment groups (Table 3; Figs 1
and 2). Similar results were obtained with the 24-h version of
the Psoriasis Symptom Inventory (data not shown).
The rapidity of the response varied by item with a majority
of subjects achieving a score of 0 by week 2 for the burning,
stinging, cracking and pain items (Fig. 3). Improvements for
the other four symptoms occurred later, but among the broda-
lumab treatment groups all items were signiﬁcantly different
at week 12 compared with placebo (Fig. 3).
At week 12, DLQI total scores and domain scores were signiﬁ-
cantly lower in the brodalumab groups than in the placebo
group
17 (Figs 1b and 4). Lower DLQI total scores were observed
as early as week 4, the earliest time point measured (Fig. 1b),
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groups were clinically meaningful (change of ≥ 57)
19 as early as
w e e k4( T a b l e 3 ) .D L Q Is c o r e sw ere signiﬁcantly improved
across all domains at week 12 in all brodalumab groups (Fig. 4).
The proportion of subjects with complete improvement of
psoriasis-related symptoms (Psoriasis Symptom Inventory total
score of ‘0’) at week 12 was signiﬁcantly greater in the broda-
lumab groups than in the placebo group (Fig. 5; Table 4). At
week 12, 41% and 55% of subjects in the 140- and 210-mg
groups, respectively, had a Psoriasis Symptom Inventory total
score of ‘0’ compared with 0% of subjects in the placebo
group (P < 00001). A signiﬁcant proportion of subjects had
a Psoriasis Symptom Inventory total score of ‘0’ as early as
week 2 in the 210-mg group and by week 4 in the 140-mg
group (Table 4). The proportions of subjects with complete
or almost complete improvement of dermatological-related
impairment of quality of life (DLQI total score of ‘0’ and ‘0
or 1’) at week 12 were signiﬁcantly greater in the brodalumab
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12, 46% and 58% of subjects in the 140- and 210-mg
groups, respectively, had a DLQI total score of ‘0’ compared
with 0% of subjects in the placebo group (P < 00001). The
proportions of subjects with no impairment to health-related
quality of life (DLQI total score 0 or DLQI total score 0 or 1)
were signiﬁcantly greater at all time points for the brodalumab
groups compared with placebo, except for the 70-mg group
at week 4 (Table 4).
Discussion
The Psoriasis Symptom Inventory is a novel PRO instrument
for evaluating the severity of psoriasis symptoms
12,13 that has
demonstrated good reliability and validity in patients with
psoriasis.
15,16 Previous analyses using pooled data from this
study found that correlations between the Psoriasis Symptom
Inventory and DLQI total scores ranged from 055 to 082
16
providing strong evidence of convergent validity of the Psoria-
sis Symptom Inventory. Known groups validity was also sup-
ported; mean Psoriasis Symptom Inventory total change scores
were signiﬁcantly different among PASI groups (P < 0001)
with greater change scores found for higher levels of PASI
improvement categories (P < 001).
16 In this study we used
the Psoriasis Symptom Inventory to assess symptom severity
and the DLQI to assess dermatology-speciﬁc quality of life in
subjects with psoriasis following treatment with brodalumab.
Brodalumab treatment resulted in signiﬁcant improvements in
psoriasis symptoms of patients with moderate-to-severe psori-
asis as measured by the Psoriasis Symptom Inventory. These
improvements in psoriasis symptoms were rapid, with signiﬁ-
cant improvements observed as early as week 2. Brodalumab
treatment also resulted in signiﬁcant improvement in derma-
tology-speciﬁc quality of life, as measured by the DLQI, as
early as week 4. These PRO improvements were consistent
with the clinical effect of brodalumab of improved PASI,
17
suggesting that improvements in psoriasis symptoms may lead
to improvements in HRQoL.
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responsive to changes in psoriasis severity. Psoriasis Symptom
Inventory total scores differentiated groups based on PASI and
sPGA scores, with mean scores signiﬁcantly larger in those
patients rated by clinicians as having more severe psoriasis.
16
In the current study, numerically increasing trend among doses
regarding Psoriasis Symptom Inventory response was observed,
similar to the dose response observed for the clinical effect of
brodalumab as assessed by PASI improvements;
17 however, the
current study was not adequately powered to differentiate for-
mally among doses, especially the top three doses. The
observed changes in Psoriasis Symptom Inventory total scores
for the 140- and 210-mg doses were more than twice the
baseline SD, indicating large improvements in symptoms.
Signiﬁcant improvement in DLQI for brodalumab vs. pla-
cebo surpassed the disease-speciﬁc minimal important differ-
ence of 57 for this measure
19 as early as week 4,
demonstrating that brodalumab can rapidly provide clinically
meaningful HRQoL improvements in patients with moderate-
to-severe psoriasis. Moreover, > 40% of subjects in the 140-
and 210-mg brodalumab groups had complete improvement
in psoriasis symptom severity (Psoriasis Symptom Inven-
tory = 0) and in impairment to quality of life (DLQI = 0) by
week 8, whereas no subjects in the placebo group had
complete improvement in Psoriasis Symptom Inventory or
DLQI at any time point. These results signify the positive
impact of brodalumab treatment on the debilitating effects of
psoriasis.
All items in the Psoriasis Symptom Inventory were found to
change in the same direction over time and each item demon-
strated a signiﬁcant improvement vs. placebo. Although all the
Psoriasis Symptom Inventory items scores improved signiﬁ-
cantly among the brodalumab groups by week 12, some
symptoms improved more rapidly than others. Over 40% of
subjects in the 140-mg brodalumab group had complete
improvement of the burning, stinging, cracking and pain
items by week 2, whereas the improvements in the other
symptoms were not reported until week 4 (scaling and ﬂak-
ing) or week 8 (itch and redness). These results suggest that
treatment may relieve some psoriasis symptoms faster than
other, more persistent, symptoms. This is consistent with
anecdotal patient reports of burning, stinging and bleeding
accompanying cracking or sloughing of severe plaques, while
itch and redness persist until the plaques are resolved (per-
sonal communication, Mona Martin). Additional research with
larger samples is needed to explore these differences in symp-
tom remission. Little content overlap exists between the Psori-
asis Symptom Inventory and DLQI; although the DLQI
contains one symptom item, it is a broad questionnaire on
overall symptoms in contrast to the speciﬁc questions on indi-
vidual symptoms in the Psoriasis Symptom Inventory.
Overall, this study demonstrated that substantial clinical
improvements across treatment groups in patients with psoria-
sis treated with brodalumab were associated with signiﬁcant
improvements in HRQoL and symptoms as measured by two
dermatology-speciﬁc measures. Brodalumab improved psoriasis
symptoms measured by the Psoriasis Symptom Inventory as
well as more distal impacts on HRQoL measured by the DLQI.
The combination of symptoms and HRQoL provide a compre-
hensive assessment of patients’ experience with the disease and
treatment. Distressing symptoms can often cause impairment
to HRQoL. Previous research has demonstrated a high correla-
tion between the Psoriasis Symptom Inventory and DLQI,
16
thus it is possible that improvement in symptom severity can
be accompanied by improvement in dimensions of HRQoL.
More research to evaluate the relationship between psoriasis
symptoms and HRQoL may help to understand better the
impact of symptom improvement in patients with psoriasis.
This would allow for the use of the Psoriasis Symptom Inven-
tory in research settings to better evaluate symptoms from the
patient’s perspective. Often, physicians’ perspectives of con-
trolled disease do not align with the patient’s perspective.
Therefore the Psoriasis Symptom Inventory, as a PRO of psoria-
sis symptom severity, can serve as another tool for evaluating
the impact of psoriasis symptoms and treatment effectiveness.
There were a number of limitations of this study. The
results were from a relatively small study. Therefore, statistical
results should be interpreted with caution. Data were from a
phase II clinical trial, and study inclusion and exclusion crite-
ria and demographic proﬁle of patients willing to participate
in a clinical trial may impact generalizability of the results.
The 12-week evaluation captured only short-term improve-
0
20
40
60
80
100
P
r
o
p
o
r
t
i
o
n
 
o
f
 
s
u
b
j
e
c
t
s
 
w
i
t
h
p
s
o
r
i
a
s
i
s
 
s
y
m
p
t
o
m
 
i
n
v
e
n
t
o
r
y
s
c
o
r
e
 
=
 
0
 
(
%
)
0
20
40
60
80
100
Placebo 70 mg 140 mg 210 mg 280 mg
Brodalumab Q2W Brodalumab Q4W
Placebo 70 mg 140 mg 210 mg 280 mg
Brodalumab Q2W Brodalumab Q4W
P
r
o
p
o
r
t
i
o
n
 
o
f
 
s
u
b
j
e
c
t
s
 
w
i
t
h
D
L
Q
I
 
s
c
o
r
e
 
=
 
0
/
1
 
(
%
)
DLQI = 0 DLQI = 1
Fig 5. Proportion of subjects with a complete or almost complete
response at week 12. (a) Proportion of subjects with a Psoriasis
Symptom Inventory total score of 0 at week 12. (b) Proportion of
subjects with a Dermatology Life Quality Index (DLQI) score of 0 or
1. Q2W, every 2 weeks; Q4W, every 4 weeks.
© 2013 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2014) 170, pp705–715
Patient-reported outcomes of brodalumab in psoriasis, K.B. Gordon et al. 713ments and these results need to be conﬁrmed by larger, phase
III studies. There was some evidence of differential discontinu-
ation rates between the placebo and brodalumab groups, and
the use of LOCF imputation may have introduced some bias
into the treatment comparisons favouring the placebo group.
However, the large changes in symptoms and HRQoL
observed suggest that the bias may be minimal. This study
focused on the 7-day version of the Psoriasis Symptom
Inventory, because the 24-h version was completed only at
designated study visits and not administered as a daily diary.
In a separate study, the 24-h version and the 7-day version
were found to be comparable with respect to measurement
properties.
15 The 24-h version administered as a daily diary
may be more suitable in a clinical trial setting where rapid
change in symptoms is expected. For clinical practice or in an
observational research setting, the 7-day version will be more
Table 4 Psoriasis Symptom Inventory and Dermatology Life Quality Index (DLQI) threshold scores over time
Placebo (n = 38)
Brodalumab
Q2W Q4W
70 mg (n = 39) 140 mg (n = 39) 210 mg (n = 40) 280 mg (n = 42)
Proportion of subjects with Psoriasis Symptom Inventory total score = 0
Baseline
n/N (%) 0/33 (0) 0/37 (0) 0/37 (0) 0/39 (0) 0/42 (0)
P-value N/A N/A N/A N/A
Week 2
n/N (%) 0/34 (0) 4/38 (10) 2/36 (6) 4/38 (10) 6/41 (15)
P-value 0047 0154 0043 0020
Week 4
n/N (%) 0/37 (0) 2/38 (5) 6/39 (15) 14/40 (35) 9/41 (22)
P-value 0161 0012 < 00001 0002
Week 8
n/N (%) 0/37 (0) 6/38 (16) 17/39 (44) 20/40 (50) 7/41 (17)
P-value 0012 < 00001 < 00001 0007
Week 12
n/N (%) 0/37 (0) 7/38 (18) 16/39 (41) 22/40 (55) 13/41 (32)
P-value 0006 < 00001 < 00001 00001
Proportion of subjects with DLQI total score = 0
Baseline
n/N (%) 0/37 (0) 0/37 (0) 0/39 (0) 0/40 (0) 1/42 (2)
P-value N/A N/A N/A 0341
Week 4
n/N (%) 0/36 (0) 3/38 (8) 8/39 (20) 14/39 (36) 8/40 (20)
P-value 0088 0004 < 00001 0004
Week 8
n/N (%) 0/37 (0) 5/38 (13) 17/39 (44) 21/40 (52) 10/41 (24)
P-value 0023 < 00001 < 00001 00009
Week 12
n/N (%) 0/37 (0) 6/38 (16) 18/39 (46) 23/40 (58) 14/41 (34)
P-value 0012 < 00001 < 00001 < 00001
Proportion of subjects with DLQI total score = 0/1
Baseline
n/N (%) 0/37 (0) 0/37 (0) 2/39 (5) 0/40 (00) 2/42 (5)
P-value N/A 0161 N/A 0175
Week 4
n/N (%) 2/36 (6) 8/38 (21) 14/39 (36) 22/39 (72) 12/40 (30)
P-value 0054 0002 < 00001 0006
Week 8
n/N (%) 2/37 (5) 9/38 (24) 24/39 (62) 29/40 (72) 18/41 (44)
P-value 0026 < 00001 < 00001 < 00001
Week 12
n/N (%) 2/37 (5) 10/38 (26) 25/39 (64) 29/40 (72) 23/41 (56)
P-value 0015 < 00001 < 00001 < 00001
P-value is based on Cochran–Mantel–Haenszel test stratiﬁed by body mass index group (≤ 35, > 35) and is for comparison between each
brodalumab group and placebo without multiplicity adjustment; last observation carried forward was used to impute missing data. N/A, not
applicable; Q2W, every 2 weeks; Q4W, every 4 weeks.
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dule. Additional research is being undertaken to evaluate the
interpretability of Psoriasis Symptom Inventory change scores
and thresholds. Similar to the DLQI score of 0, the clinical rel-
evance of the best possible score of the Psoriasis Symptom
Inventory (Psoriasis Symptom Inventory = 0) is apparent as it
is an indicator of the subject reporting no severity for all eight
psoriasis-speciﬁc symptoms.
In conclusion, brodalumab treatment provided signiﬁcant
improvement in psoriasis symptoms and functional outcomes
in patients with moderate-to-severe psoriasis. These improve-
ments could be distinguished between treatment with broda-
lumab and placebo as well as between brodalumab dose
regimens. These ﬁndings demonstrate that observed clinical
improvements in disease severity in response to brodalu-
mab
17 parallel important improvements in patient-reported
symptoms and HRQoL in patients with moderate-to-severe
psoriasis.
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